Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of UX007 (Triheptanoin) in Korean Patients with Long-chain Fatty Acid Oxidation Disorders
KCT0006756Phase 2Not yet recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of triheptanoin in long-chain fatty acid oxidation disorder (LC-FAOD), sponsored by Ultragenyx Pharmaceutical Inc.. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
triheptanoin
03
Conditions
long-chain fatty acid oxidation disorder (LC-FAOD)
Beyond the preview
Go deeper on KCT0006756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006756.